Park Avenue Securities LLC Purchases 633 Shares of Illumina, Inc. (NASDAQ:ILMN)

Park Avenue Securities LLC grew its position in Illumina, Inc. (NASDAQ:ILMN) by 7.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,005 shares of the life sciences company’s stock after buying an additional 633 shares during the period. Park Avenue Securities LLC’s holdings in Illumina were worth $1,203,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of ILMN. Millennium Management LLC boosted its stake in Illumina by 305.0% in the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock valued at $155,067,000 after acquiring an additional 1,118,747 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Illumina in the 2nd quarter worth $77,628,000. Massachusetts Financial Services Co. MA increased its position in Illumina by 148.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock valued at $137,735,000 after buying an additional 631,294 shares in the last quarter. Janus Henderson Group PLC raised its stake in Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after buying an additional 625,245 shares during the last quarter. Finally, Iron Triangle Partners LP acquired a new stake in Illumina in the third quarter worth about $57,380,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Performance

NASDAQ ILMN opened at $136.67 on Monday. The stock has a market capitalization of $21.68 billion, a price-to-earnings ratio of -13.72 and a beta of 1.11. The stock has a 50-day moving average of $139.60 and a 200 day moving average of $133.57. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a twelve month low of $100.08 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business’s revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.33 EPS. Sell-side analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ILMN. Royal Bank of Canada upped their price objective on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. TD Cowen raised their price target on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Canaccord Genuity Group lifted their price objective on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. upped their target price on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, Stephens lifted their price target on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Eight research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $165.63.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.